1 *Original research*

2

3 **Acquired neutralizing breadth against SARS-CoV-2 variants including Omicron**
 4 **after three doses of mRNA COVID-19 vaccination and the vaccine efficacy**

5

6 Koichi Furukawa, MD, Lidya Handayani Tjan, MD, PhD, Yukiya Kurahashi, MD,
 7 Silvia Sutandhio, MD, Mitsuhiro Nishimura, PhD, Jun Arie, DVM, PhD, Yasuko Mori,
 8 MD, PhD

9 Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate
 10 School of Medicine, Kobe, Hyogo 650-0017, Japan

11

12 **Corresponding author:**

13 Prof Yasuko Mori

14 Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate
 15 School of Medicine.

16 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo Japan, 650-0017

17 Tel: +81-78-382-6272 Fax: +81-78-382-6879

18 E-mail: ymori@med.kobe-u.ac.jp

19 **ABSTRACT**

20 To investigate the induction of neutralizing antibodies against Omicron after two and
 21 three vaccine doses in recipients of different ages. Physicians at Kobe University
 22 Hospital who had received the second dose of the BNT162b2 mRNA vaccine. At 2
 23 months after the second vaccinations, the positive rate of neutralizing antibody against
 24 Omicron was 28%, and the titer was significantly lower than those against other
 25 variants, 11.8-fold and 3.6-fold lower than those against D614G and Delta, respectively.
 26 Unlike Delta, that positive rates of neutralizing antibody against Omicron were low in
 27 all age groups, and there was no significant difference in titers among age groups. Seven
 28 months after the 2nd dose, the positive rate of neutralizing antibody against Omicron
 29 decreased to 6%, but after the booster, 3rd vaccination, it increased to 100%, and the
 30 titer was much higher than those at 2 and 7 months post-vaccination, 32-fold and
 31 39-fold respectively. The booster vaccination effect was also observed in the younger at
 32 41-fold, middle-aged at 43-fold, and older at 27-fold groups compared to the 7-month
 33 titers. Surprisingly, higher-than-predicted titers of the neutralizing antibodies against
 34 Omicron were induced after the booster vaccination regardless of recipient age, while
 35 this effect was not observed after two doses, indicating the induction of antibodies

36 against common epitopes by the booster vaccination. Three doses can be confidently

37 recommended to suppress the pandemic.

38

39 **Introduction**

40 The coronavirus disease 2019 (COVID-19) pandemic declared by the World
41 Health Organization (WHO) in March 2020 continues to affect all countries around the
42 world. Based on the WHO COVID-19 dashboard as of 20 January 2022, there have
43 been more than 332 million confirmed cases with more than 5.5 million deaths
44 worldwide.¹ Currently, the Omicron variant (B.1.1.529) of the original severe acute
45 respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly spreading and has become
46 the dominant variant all over the world, including Japan.²⁻⁶ In efforts to control the
47 pandemic, several vaccine platforms have been developed using the original
48 SARS-CoV-2 virus (Wuhan-1) as the template, and the BNT162b2 mRNA vaccine
49 (Comirnaty[®], BioNTech-Pfizer, Mainz, Germany/New York, U.S.) was granted an
50 emergency use authorization by the U.S. Food and Drug Administration (FDA) in
51 December 2020, after showing high effectiveness in preventing infection.⁷

52 However, since April 2020, a variant bearing a D614G mutation of the spike
53 protein and several SARS-CoV-2 variants classified as variants of concern (VOC) or
54 variants of interest (VOI) by the WHO have emerged and spurred the spread of
55 infection worldwide. As of this manuscript's writing, SARS-CoV-2 variants classified as
56 VOCs include Alpha (B.1.1.7) first detected in the UK,⁸⁻¹⁰ Beta (B.1.351) from South
57 Africa,¹¹⁻¹⁴ Gamma (P.1) from Brazil,^{15,16} Delta (B.1.617.2) from India,¹⁷ and Omicron

58 (B.1.1.529) from South Africa and Bostwana, which is the latest VOC (detected in early
59 November 2021).^{18,19} The emergence of these variants poses a tremendous challenge
60 because the vaccine efficacy is negatively impacted by these variants.

61 In particular, the Beta and Gamma variants carry the E484K mutation in the
62 receptor binding domain (RBD) of the spike protein, which allows evasion of
63 neutralizing antibodies against the original SARS-CoV-2, further compromising the
64 currently available therapy.²⁰⁻²² The Delta variant has L452R, T478K, and P681R
65 mutations in the RBD, which increases the virus transmissibility—leading to a
66 higher viral load in infected individuals.^{23,24} However, the novel Omicron variant is the
67 most mutated variant, with over 30 mutations in the spike protein and 15 mutations in
68 the RBD.²⁵ There is thus great concern about the Omicron variant's higher
69 transmissibility and immune escapes from COVID-19 vaccines and antibody-based
70 therapies.²⁶⁻²⁹ It has also been demonstrated that vaccine-induced neutralizing antibody
71 responses decrease with increased time post-vaccination.^{30,31}

72 To counteract the decline of the neutralizing antibody response over time and the
73 emergence of new variants including Omicron, a third dose of vaccination, which has
74 been called a "booster vaccination," has been approved and administered to individuals
75 who were vaccinated >6 months ago; the booster vaccination has been shown to

effectively induce a high titer of neutralizing antibody.³² However, it is unclear whether the effective neutralizing antibody against Omicron can be obtained by two or three doses of vaccination compared to the other variants. It is also not yet clear whether the characteristics of the vaccine's recipients or side effects are related to the acquired immunity.

Here, we investigated the neutralizing breadth of sera against D614G, Alpha, Beta, Gamma, Delta, Kappa, and Omicron variants which were obtained from 82 vaccinated physicians without a history of SARS-CoV-2 infection, and we analyzed the correlations between the neutralizing antibody titers and the recipients' background and side effects. We also followed and analyzed the neutralizing antibody titers against D614G, Delta, and Omicron in individuals after they received the booster (third dose of) vaccination.

Participants and Methods

Participant recruitment

From June 2021 to July 2021, blood samples from 82 physicians at Kobe University Hospital (Kobe, Japan) who had already received the second vaccination of the BNT162b2 mRNA COVID-19 vaccine and had never tested positive for SARS-CoV-2

94 infection were collected and analyzed (1st trial). As the 2nd trial, blood samples were
 95 collected again from the participants during the period from October to November 2021.
 96 In a 3rd trial, blood samples from the 72 participants who received booster vaccination
 97 were collected in January 2022 and analyzed. The sera of 24 unvaccinated and healthy
 98 adults were also collected and confirmed to have no antibody against SARS-CoV-2;³³
 99 these sera were used as the negative control group. This study was carried out after
 100 written consent was obtained from all participants. No statistical methods were used to
 101 predetermine the sample size.

102

103 *Questionnaire about side effects*

104 When blood samples were collected, a questionnaire was used to obtain the participants'
 105 background characteristics and information about any side effects that occurred within
 106 the first week after the first, second, and booster vaccinations. The contents of the
 107 questionnaire included age, sex, symptoms after vaccination such as fever ($>37.5^{\circ}$),
 108 general fatigue, injection site pain (0: none, 1: mild, 2: moderate, 3: severe), the side of
 109 the injected arm, and others. The degree of injection site pain was subjectively
 110 determined by each participant.

111

112 *Measurement of neutralizing activity against SARS-CoV-2*

113 The neutralization assay was performed using authentic viruses as recently
114 described.^{34,35}

115

116 *Preparation of SARS-CoV-2 variants*

117 We used the SARS-CoV-2 Biken-2 (B2) strain with a D614G mutation as a
118 conventional variant (accession no. LC644163); it was provided by the BIKEN
119 Innovative Vaccine Research Alliance Laboratories (Osaka, Japan). The other variants,
120 i.e., Alpha (GISAID ID: EPI_ISL_804007), Beta (GISAID ID: EPI_ISL_1123289),
121 Gamma (GISAID ID: EPI_ISL_833366), Delta (GISAID ID: EPI_ISL_2158617),
122 Kappa (GISAID ID: EPI_ISL_2158613), and Omicron (GISAID ID:
123 EPI_ISL_7418017) had been isolated and were provided by the National Institute of
124 Infectious Disease, Japan (Tokyo). Each variant was confirmed by the cDNA sequence
125 of its spike gene.

126

127 *Statistical analysis*

128 GraphPad Prism software (ver. 8.4.3) and STATA software (ver. 14.2) were used for the
129 statistical analysis and preparation of figures. The Friedman test was used to compare

130 the neutralizing antibody titer among the seven variants. The Mann-Whitney U-test or
131 Kruskal-Wallis test was used to compare the neutralizing antibody titer or age among
132 the different groups of participants. If a significant difference was found by the
133 Friedman test or Kruskal-Wallis test, Dunn's multiple comparison test was then
134 performed. Results were considered significant when p-values were <0.05 (two-tailed).

135

136 *Ethical approval*

137 This study was approved by the ethical committee of Kobe University Graduate School
138 of Medicine (approval code: B200200).

139

140 **Results**

141 *Participant characteristics and side effects after the first, second, and third vaccine*

142 *doses*

143 The demographic characteristics of the participants are summarized in Table 1. The
144 median (interquartile [IQR]) numbers of days between the second dose of vaccination
145 and the collection of serum samples in the 1st and 2nd trials were 53 [46–59] and 199
146 [192–203], respectively (hereinafter referred to as "2 months" and "7 months" after the
147 vaccination). The median number of days between the booster vaccination and the

148 collection of serum samples in the 3rd trial was 16 days. Because most of the physicians
149 working in the hospital were men, most (71 of the 82) participants were males (86.6%).

150 The side effects reported by the participants after the first, second, and booster
151 vaccination are also listed in Table 1. Side effects at the time of the booster vaccination
152 were as follows: fever in 24 participants (33%), general fatigue in 45 (63%), and
153 injection site pain in 65 (89%) (15 mild, 35 moderate, and 15 severe). The frequency of
154 systemic reactions including fever and fatigue increased in order, with the booster
155 vaccination being the most frequent, but that of injection site pain did not change. No
156 participant had serious adverse events.

157

158 *Neutralizing activity against Omicron compared with the other variants at 2 months*
159 *post-vaccination*

160 Although the neutralizing antibody titer varied, all 82 sera had neutralizing activity
161 against D614G and Alpha. In contrast, most (but not all) of the sera had neutralizing
162 activity against the Beta, Gamma, Delta, and Kappa variants; neutralizing antibody
163 positive rates against the respective variants were 87.8%, 95.1%, 92.7%, and 90.2% of
164 the participants. Surprisingly however, only 28% of the participants had the neutralizing
165 activity against Omicron (Fig. 1A). The comparison of the antibody titers for each

variant revealed that the antibody titers against Omicron were significantly lower than those against the six other variants (Fig. 1B). The average neutralizing antibody titers against Omicron were 11.8-fold (95%CI: 9.9–13.9) lower than that against D614G, 7.3-fold (95%CI: 6.3–8.5)) lower than that against Alpha, 3.2-fold (95%CI: 2.6–3.8)) lower than that against Beta, 4.9-fold (95%CI: 4.1–5.9)) lower than that against Gamma, 3.6-fold (95%CI: 3.1–4.2)) lower than that against Delta, and 2.6-fold (95%CI: 2.2–3.0) lower than that against Kappa.

The neutralizing antibody titer against D614G was significantly higher than those against Beta (3.6-fold; 95%CI: 3.0–4.3), Gamma (2.3-fold; 95%CI: 1.9–2.8), Delta (3.2-fold; 95%CI: 2.7–3.7), and Kappa (4.5-fold; 95%CI: 3.8–5.2).

Neutralizing activity against Omicron and the other variants at 2 months after

vaccination in each age group

We had divided the participants into three groups by age: the 31 participants (37.8%) who were ≤ 38 years old were classified as the younger group; the 32 participants (39.0%) aged 39–58 years old comprised the middle-aged group; and the 19 participants (23.2%) who were ≥ 59 years old constituted the older group (Table 1). Although all of the participants' sera showed neutralizing activity against D614G and Alpha regardless

184 of age, sera with negative neutralizing activity against other variants were observed in
 185 all age groups, and the negative proportion tended to be higher in the older group (Fig.
 186 2A). The positive rate of sera with neutralizing antibody against Omicron was low in all
 187 three age groups; only 32% had the neutralizing antibody against Omicron even in the
 188 younger age (≤ 38 yrs) group. The comparison of neutralizing antibody titers among the
 189 three age groups showed results similar to the positive rate: the median [range] of
 190 neutralizing antibody titer against Delta was significantly lower in the older age group
 191 (3 [$<2-8$]) compared to the other two groups: (4 [$<2-32$] vs. the younger group, $p=0.03$)
 192 and (4 [$<2-32$] vs. the middle-aged group, $p=0.04$). Similar results were also obtained
 193 for the median [range] of neutralizing titer against Kappa: (2 [$<2-4$] in the older group)
 194 versus (4 [$<2-16$] in the younger group, $p=0.02$) and (4 [$<2-16$] in the middle-aged
 195 group, $p=0.05$) (Fig. 2B).

196

197 *Side effect-related differences in neutralizing activity and recipient characteristics*

198 Our comparison of neutralizing antibody titers against any of the SARS-CoV-2 variants
 199 showed no significant difference in the percentages of participants with and without side
 200 effects, e.g., fever, injection site pain, and fatigue (eFig. 1A in Supplement). However,
 201 the comparison of participant ages and side effects revealed that the median age of the

202 participants with fever was significantly younger than that of the participants without
 203 fever: 37 years (range 28–64 yrs) versus 46 (29–68) years, $p=0.02$. There were no
 204 significant between-group differences in the median age of the participants with or
 205 without fatigue (44 years [range 28–68 yrs] vs. 39 [28–64], $p=0.97$) or regarding the
 206 degrees of injection site pain (none: 41 [31–68] vs. mild: 50 [30–64] vs. moderate: 42
 207 [28–64] vs. severe: 39 [36–51]) (eFig. 1B in Supplement).

208

209 *Neutralizing activity against three variants at 7 months after two vaccine doses and*
 210 *after the booster*

211 We determined the positive rates of neutralizing antibody against D614G, Delta, and
 212 Omicron at 2 and 7 months after the two vaccine doses. At 7 months after the
 213 vaccination, 93% of the 82 participants had neutralizing antibody against D614G, 67%
 214 against Delta, and only 6% against Omicron (Fig. 3A). However, surprisingly, after the
 215 booster vaccination, all 72 participants who had received the booster had the
 216 neutralizing antibody against these three variants. Figure 3B illustrates the changes in
 217 the neutralizing antibody titers against these variants during the same period. The
 218 neutralizing antibody titers against D614G and Delta were significantly decreased at 7
 219 months compared to those at 2 months after the second vaccination: D614G, 2.2-fold

(95%CI: 1.9–2.5) lower; Delta, 2.1-fold (95%CI: 1.8–2.4) lower. Although the neutralizing antibody titers against Omicron also tended to decrease during this period, no significant difference was observed: median [range] neutralizing antibody titer was <2 [<2 – 2] at 2 months versus <2 [<2 – 4] at 7 months ($p=0.54$).

Notable, the neutralizing antibody titers after the booster vaccination were much higher than those at 2 and 7 months post-vaccination against all variants, as follows. D614G: 13-fold (95%CI: 11–16) and 31-fold (95%CI: 25–38) higher than that at 2 and 7 months, respectively; Delta: 16-fold (13–20) and 35-fold (95%CI: 29–43); Omicron: 32-fold (27–37) and 39-fold (95%CI: 32–46).

Comparison of neutralizing antibody titers after booster vaccination in the three age groups

We compared the effects of booster vaccination on the neutralizing antibody titers in each age group (Fig. 4A–C). Seven months after the 2nd vaccination, the neutralizing antibody titers against D614G and Delta tended to be low in the older age group, and those against Omicron were much lower in all three age groups. However, the booster vaccination effectively increased the neutralizing antibody titers for all three variants including Omicron, regardless of the participants' ages, as follows. The younger,

238 middle-aged, and older groups values after the booster compared to the values at 7
239 months were D614G: 28-fold (22–36), 28-fold (95%CI: 18–42), and 47-fold (95%CI:
240 29–75) greater; those for Delta were 32-fold (95%CI: 23–44), 38-fold (95%CI: 26–55),
241 and 39-fold (95%CI: 29–52) greater; and those for Omicron were 41-fold (95%CI:
242 30–56), 43-fold (95%CI: 32–58), and 27-fold (95%CI: 20–36) greater, respectively.

243

244 **Discussion**

245 We evaluated neutralizing activities against authentic SARS-CoV-2 variants in the sera
246 of adults vaccinated with two or three doses of the BNT162b2 mRNA vaccine. We also
247 analyzed the changes in the neutralizing antibody titers after the booster vaccination in
248 different age groups, and we evaluated the relationships between side effects, the
249 participants' ages, and the acquired neutralizing antibody titer. This is the first report on
250 the detailed efficacy of two doses and the booster vaccination for a Japanese population
251 using authentic viruses including Delta and Omicron.

252 Our results demonstrated that only 28% of the vaccine recipients had neutralizing
253 antibodies against Omicron at 2 months after their second vaccination, and the
254 neutralizing antibody titer against Omicron was significantly lower than those against
255 all six of the other variants tested. This low positive rate of neutralizing antibody against

256 Omicron was distinctly different from what we observed for other variants, in which
257 88%–100% of recipients had the neutralizing antibody against other variants at 2
258 months after the vaccination, suggesting that the neutralizing antibody against Omicron
259 cannot be sufficiently induced by only two doses of vaccination, as has been noted in
260 other reports.^{28,29,36,37}

261 At 7 months after the second vaccination, that tendency was even more
262 pronounced, with only 6% of the participants showing neutralizing antibodies against
263 Omicron, suggesting a high risk of breakthrough infection or reinfection. Regarding the
264 potential cause of this finding, it has been reported that mutations on the spike protein
265 of Omicron, especially K417N, N440K, G446S, S477N, T478K, E484A, Q493R,
266 G496S, Q498R, N501Y, and Y505H, were responsible for the variant's broad evasion
267 from antibodies.³⁸ In case of the Delta variant, L452R, T478K, and P681R have been
268 reported to promote the interaction between the spike and angiotensin-converting
269 enzyme 2 (ACE2) receptor by inducing structural changes in the binding domain,
270 resulting in immune evasion and increased transmissibility.³⁹⁻⁴¹ In our present
271 investigation, 66.7% of the participants had neutralizing antibodies against Delta at 7
272 months after their second vaccination, suggesting that neutralizing antibodies against
273 Delta could be more easily induced by two doses of vaccination compared to Omicron.

274 We also observed that the booster vaccination induced much higher levels of
275 neutralizing antibodies against Omicron compared to those after two vaccine doses.
276 This may indicate that the booster vaccination can induce sufficient immunity against
277 Omicron and the other variants that may appear in the future, by inducing neutralizing
278 antibodies that recognize common epitopes, and by promoting affinity maturation of the
279 neutralizing antibody.⁴²⁻⁴⁴

280 Our comparison of neutralizing antibody titers among the three age groups at 2
281 months after the second vaccination showed that neutralizing activity against all seven
282 tested variants tended to be lower in the older participants (and the activity was
283 significantly lower only for Delta and Kappa). However, our findings of no significant
284 difference in the neutralizing antibody titers against Omicron among the present age
285 groups and that only 32% of the participants in the youngest group had neutralizing
286 antibodies reflects the universally low neutralizing activity for Omicron, unlike that for
287 Delta.

288 However, the increase in the neutralizing antibody level induced by the booster
289 vaccination did not show a large difference among the three age groups, and the
290 neutralizing antibody against Omicron was sufficiently induced in all age groups,
291 suggesting that the effect of the booster vaccination is guaranteed even in older

292 individuals and that the booster should be recommended for all individuals regardless of
293 age.

294 The proportion of participants who had fever or general fatigue after vaccination
295 in this study increased from the first dose to the third dose of vaccination, whereas the
296 distribution of injection site pain was almost the same across the doses, indicating that
297 the vaccinations' systemic side effects such as fever and general fatigue may increase
298 mainly as a consequence of a stronger immunological response for the second and third
299 doses.⁴⁵⁻⁴⁷ However, we did not detect a correlation between the neutralizing antibody
300 titer induced by two doses of vaccination and vaccination-related side effects, indicating
301 that fever and other side effects are not specific immune reactions to the viral spike
302 protein, but rather may be specific to other materials contained in the vaccine. This
303 relationship remains controversial, and further studies including a booster vaccination
304 are necessary to evaluate it.⁴⁸

305 Overall, our findings showed that a sufficient neutralizing antibody titer against
306 Omicron could not be induced by only two vaccine doses, suggesting a high risk of
307 breakthrough infection or reinfection. Moreover, the elderly may not be equally
308 protected from Delta and other variants. Although systemic side effects such as fever
309 and general fatigue may increase, our study revealed that the third dose of the

310 vaccination effectively induced neutralizing antibodies against Omicron regardless of
311 the recipients' age. The booster should therefore be recommended to help prevent the
312 further spread of the COVID-19 pandemic.

313

314 **Acknowledgments**

315 We thank Kazuro Sugimura MD, PhD (Superintendent, Hyogo Prefectural Hospital
316 Agency and Professor, Kobe University) for his full support to promote this study. We
317 thank BIKEN Innovative Vaccine Research Alliance Laboratories for providing
318 SARS-CoV-2 B2 strain. We thank the National Institute of Infectious Disease Japan for
319 providing SARS-CoV-2 Alpha, Beta, Gamma, Delta, Kappa and Omicron variants.

320

321 *Authors' Statement*

322 All authors attest that they meet the ICMJE criteria for authorship.

323

324 *Conflicts of Interest*

325 All authors declare no conflicts of interest with respect to this.

326

327 *Funding*

328 This work was supported by Hyogo Prefectural Government. The funders had no role in
329 study design, data collection and analysis, decision to publish, or preparation of the
330 manuscript.

331

332 *Presentation at meetings*

333 This study has never been presented anywhere.

334

335 *Contributions*

336 All authors contributed to the concept of this article. KF drafted the manuscript; YM
337 provided revisions; KF, YK, JA, MN, and YM analyzed the data; KF, YK, LT, and SS
338 did the experiments; YM supervised the experiments; KF collected the samples; YM
339 conducted the project; All authors approved the final version of the manuscript.

340

341 **References :**

- 342 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Accessed
343 20 January, 2022, <https://covid19.who.int>
- 344 2. Maruki T, Iwamoto N, Kanda K, et al. Two cases of breakthrough SARS-CoV-2
345 infections caused by the Omicron variant (B.1.1.529 lineage) in international
346 travelers to Japan. *Clin Infect Dis*. Jan 03 2022;doi:10.1093/cid/ciab1072
- 347 3. Abbasi J. Omicron Has Reached the US-Here's What Infectious Disease Experts
348 Know About the Variant. *JAMA*. Dec 28 2021;326(24):2460-2462.
349 doi:10.1001/jama.2021.22619
- 350 4. Graham F. Daily briefing: Omicron was already spreading in Europe. *Nature*. Dec
351 01 2021;doi:10.1038/d41586-021-03610-3
- 352 5. Gu H, Krishnan P, Ng DYM, et al. Probable Transmission of SARS-CoV-2
353 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021. *Emerg*
354 *Infect Dis*. Dec 03 2021;28(2)doi:10.3201/eid2802.212422
- 355 6. Torjesen I. Covid restrictions tighten as omicron cases double every two to three
356 days. *BMJ*. Dec 09 2021;375:n3051. doi:10.1136/bmj.n3051
- 357 7. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2
358 mRNA Covid-19 Vaccine. *N Engl J Med*. 12 2020;383(27):2603-2615.
359 doi:10.1056/NEJMoa2034577
- 360 8. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L.
361 Risk of mortality in patients infected with SARS-CoV-2 variant of concern
362 202012/1: matched cohort study. *BMJ*. 03 2021;372:n579. doi:10.1136/bmj.n579
- 363 9. Davies NG, Jarvis CI, Edmunds WJ, et al. Increased mortality in community-tested
364 cases of SARS-CoV-2 lineage B.1.1.7. *Nature*. 05 2021;593(7858):270-274.
365 doi:10.1038/s41586-021-03426-1
- 366 10. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility
367 assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom,
368 October to November 2020. *Euro Surveill*. 01
369 2021;26(1)doi:10.2807/1560-7917.ES.2020.26.1.2002106
- 370 11. Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from
371 neutralization by convalescent plasma. *Nature*. 05 2021;593(7857):142-146.
372 doi:10.1038/s41586-021-03471-w
- 373 12. Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2
374 variant B.1.351 from natural and vaccine-induced sera. *Cell*. 04
375 2021;184(9):2348-2361.e6. doi:10.1016/j.cell.2021.02.037

- 376 13. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of
377 concern in South Africa. *Nature*. 04 2021;592(7854):438-443.
378 doi:10.1038/s41586-021-03402-9
- 379 14. Bian L, Gao F, Zhang J, et al. Effects of SARS-CoV-2 variants on vaccine efficacy
380 and response strategies. *Expert Rev Vaccines*. 04 2021;20(4):365-373.
381 doi:10.1080/14760584.2021.1903879
- 382 15. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1
383 SARS-CoV-2 lineage in Manaus, Brazil. *Science*. 05 21 2021;372(6544):815-821.
384 doi:10.1126/science.abh2644
- 385 16. Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of
386 SARS-CoV-2. *Cell*. 05 27 2021;184(11):2939-2954.e9.
387 doi:10.1016/j.cell.2021.03.055
- 388 17. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of
389 concern are emerging in India. *Nat Med*. Jul 2021;27(7):1131-1133.
390 doi:10.1038/s41591-021-01397-4
- 391 18. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the
392 COVID-19 pandemic. *Lancet*. 12 11 2021;398(10317):2126-2128.
393 doi:10.1016/S0140-6736(21)02758-6
- 394 19. Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS-CoV-2
395 Omicron (B.1.1.529) Variant of Concern and its global perspective. *J Med Virol*.
396 Dec 14 2021;doi:10.1002/jmv.27524
- 397 20. Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to
398 neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat Med*.
399 04 2021;27(4):717-726. doi:10.1038/s41591-021-01294-w
- 400 21. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants
401 B.1.351 and B.1.1.7. *Nature*. 05 2021;593(7857):130-135.
402 doi:10.1038/s41586-021-03398-2
- 403 22. Jangra S, Ye C, Rathnasinghe R, et al. SARS-CoV-2 spike E484K mutation reduces
404 antibody neutralisation. *Lancet Microbe*. Jul 2021;2(7):e283-e284.
405 doi:10.1016/S2666-5247(21)00068-9
- 406 23. Li Q, Wu J, Nie J, et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral
407 Infectivity and Antigenicity. *Cell*. 09 03 2020;182(5):1284-1294.e9.
408 doi:10.1016/j.cell.2020.07.012
- 409 24. Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates
410 SARS-CoV-2 pathogenesis. *Nature*. 03 2021;591(7849):293-299.
411 doi:10.1038/s41586-021-03237-4

- 412 25. Science Brief: Omicron (B.1.1.529) Variant | CDC, (n.d.). Accessed January 21,
413 2022,
414 [https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html)
415 [omicron-variant.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html)
- 416 26. Wang Y, Zhang L, Li Q, et al. The significant immune escape of pseudotyped
417 SARS-CoV-2 variant Omicron. *Emerg Microbes Infect.* Dec 2022;11(1):1-5.
418 doi:10.1080/22221751.2021.2017757
- 419 27. Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but
420 incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2
421 for infection. *medRxiv.* Dec 11 2021;doi:10.1101/2021.12.08.21267417
- 422 28. Muik A, Lui BG, Wallisch AK, et al. Neutralization of SARS-CoV-2 Omicron by
423 BNT162b2 mRNA vaccine-elicited human sera. *Science.* Jan 18 2022:eabn7591.
424 doi:10.1126/science.abn7591
- 425 29. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant
426 against antibody-mediated neutralization: Implications for control of the COVID-19
427 pandemic. *Cell.* Dec 24 2021;doi:10.1016/j.cell.2021.12.032
- 428 30. Altawalrah H. Antibody Responses to Natural SARS-CoV-2 Infection or after
429 COVID-19 Vaccination. *Vaccines (Basel).* Aug 16
430 2021;9(8)doi:10.3390/vaccines9080910
- 431 31. Tré-Hardy M, Cupaiolo R, Wilmet A, et al. Immunogenicity of mRNA-1273
432 COVID vaccine after 6 months surveillance in health care workers; a third dose is
433 necessary. *J Infect.* 11 2021;83(5):559-564. doi:10.1016/j.jinf.2021.08.031
- 434 32. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine
435 Booster against Covid-19 in Israel. *N Engl J Med.* 10 07 2021;385(15):1393-1400.
436 doi:10.1056/NEJMoa2114255
- 437 33. Nagano T, Ariei J, Nishimura M, et al. Diligent Medical Activities of a Publicly
438 Designated Medical Institution for Infectious Diseases Pave the Way for
439 Overcoming COVID-19: A Positive Message to People Working at the Cutting
440 Edge. *Clin Infect Dis.* 02 2021;72(4):723-724. doi:10.1093/cid/ciaa694
- 441 34. Furukawa K, Ariei J, Nishimura M, et al. Seroepidemiological Survey of the
442 Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing
443 Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. *JMA J.*
444 Jan 2021;4(1):41-49. doi:10.31662/jmaj.2020-0094
- 445 35. Furukawa K, Tjan LH, Sutandhio S, et al. Cross-Neutralizing Activity Against
446 SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the
447 Pandemic in Japan. *Open Forum Infect Dis.* Oct 2021;8(10):ofab430.

- doi:10.1093/ofid/ofab430
36. Peiris M, Cheng S, Mok CKP, et al. Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines. *Res Sq.* Jan 05 2022;doi:10.21203/rs.3.rs-1207071/v1
37. Yang Y, Gong X, Yang L, et al. Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees. *J Infect.* Jan 08 2022;doi:10.1016/j.jinf.2022.01.004
38. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature.* Dec 23 2021;doi:10.1038/s41586-021-04385-3
39. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. *Cell.* 06 24 2021;184(13):3426-3437.e8. doi:10.1016/j.cell.2021.04.025
40. Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity.* 08 10 2021;54(8):1853-1868.e7. doi:10.1016/j.immuni.2021.07.008
41. Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. *Nature.* Nov 25 2021;doi:10.1038/s41586-021-04266-9
42. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. *Nature.* 03 2021;591(7851):639-644. doi:10.1038/s41586-021-03207-w
43. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature.* 07 2021;595(7867):426-431. doi:10.1038/s41586-021-03696-9
44. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med.* Dec 30 2021;doi:10.1056/NEJMc2119641
45. Tré-Hardy M, Cupaiolo R, Papeux E, et al. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. *J Infect.* 08 2021;83(2):237-279. doi:10.1016/j.jinf.2021.03.025
46. Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. *JAMA.* 06 01 2021;325(21):2201-2202. doi:10.1001/jama.2021.5374

- 484 47. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2
485 vaccine after six months: a longitudinal prospective study. *Lancet Reg Health Eur.*
486 Nov 2021;10:100208. doi:10.1016/j.lanepe.2021.100208
- 487 48. Modenese A, Paduano S, Bargellini A, et al. Neutralizing Anti-SARS-CoV-2
488 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home
489 Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks
490 Apart. *Vaccines (Basel)*. Jun 15 2021;9(6)doi:10.3390/vaccines9060652
- 491

492

493 **Table 1:** Characteristics of participants and side effects of each dose of vaccination.

Characteristics	First trial ^a (n = 82)	Second trial ^b (n = 82)	Third trial ^c (n = 72)
Sex, No. (%)			
Male	71 (87)	71 (87)	61 (85)
Female	11 (13)	11 (13)	11 (15)
Age, years			
Median (IQR)	44 (33-58)	44 (33-58)	44 (33-53)
Age group, No. (%)			
≤ 38 years	31 (38)	31 (38)	31 (43)
39-58 years	32 (39)	32 (39)	27 (38)
≥ 59 years	19 (23)	19 (23)	14 (19)
Days from 2nd dose of vaccination, days (IQR)	53 (46-59)	199 (192-203)	274 (269-278)
Days from booster vaccination, days (IQR)	NA ^d	NA ^d	16 (14-21)
Side effects	1st dose of vaccination (n = 82)	2nd dose of vaccination (n = 82)	Booster vaccination (n = 72)
Fever, No. (%)	0 (0)	16 (20)	24 (33)
Fatigue, No. (%)	4 (5)	14 (17)	45 (63)
Injection site pain, No. (%)	73 (89)	71 (87)	65 (90)
mild	30 (37)	27 (33)	15 (21)

moderate	39 (48)	38 (46)	35 (49)
severe	4 (5)	6 (7)	15 (21)

Table 1 Footnotes:

^a Samples were collected from June to July 2021

^b Samples were collected from October to November 2021

^c Samples were collected in January 2022

^d NA, not applicable

500 **Figure legends**

501

502 **Fig. 1. Neutralizing antibody against SARS-CoV-2 variants at 2 months**

503 **post-vaccination.** Sera of 82 recipients were tested for neutralizing activity against the
504 SARS-CoV-2 variants D614G, Alpha, Beta, Gamma, Delta, Kappa, and Omicron. The
505 neutralizing antibody titer is represented by the highest serum dilution that did not show
506 any cytopathic effects. **(A)** The positive rate of neutralizing antibody against each
507 variant. Sera with neutralizing activity at twofold dilution (the detection limit) or higher
508 were considered positive. Numbers above the bar indicate the actual positive rate. **(B)**
509 Box plot of the neutralizing antibody titers. The ends of the box represent the upper and
510 lower quartiles, and the median is marked by the *horizontal line* inside the box. The
511 ends of the 'whiskers' represent the minimum and maximum of all data. The titers
512 against the seven variants were compared by the Friedman test and Dunn's multiple
513 comparisons test; two-tailed p-values were calculated.

514

515 **Fig. 2. Comparison of neutralizing antibodies against SARS-CoV-2 variants among**

516 **three age groups.** The 82 participants were divided into three age groups: 31
517 participants (37.8%) who were ≤ 38 years old, 32 participants who were 39–58 years old,

518 and 19 participants who were ≥ 59 years old, and the recipients' sera were tested for
 519 neutralizing activities against the seven SARS-CoV-2 variants. **(A)** The positive rates of
 520 neutralizing antibodies against each variant in the three age groups shown. Sera with
 521 neutralizing activity at twofold dilution (detection limit) or higher were considered
 522 positive. Numbers above the bar are the actual positive rate. **(B)** Comparison of
 523 neutralizing antibody titers against each variant among the age groups. Ends of the box
 524 indicate the upper and lower quartiles, and the median is marked by the *horizontal line*
 525 inside the box. Ends of the 'whiskers' = the min. and max. of all data. The
 526 Kruskal-Wallis test and Dunn's multiple comparison test were performed, and two-tailed
 527 p-values were calculated.

528

529 **Fig. 3. Neutralizing antibody after booster vaccination.** Sera of the 72 participants
 530 who received the booster vaccination were tested for neutralizing activity against
 531 D614G, Delta, and Omicron at 2 and 7 months after the two doses of vaccination and
 532 after the booster (third) vaccination. **(A)** Changes in the neutralizing antibody positive
 533 rate against each variant. Sera with neutralizing activity at twofold dilution (detection
 534 limit) or higher were considered positive. Numbers above the bar: the actual positive
 535 rate. **(B)** Changes in the neutralizing antibody titers against each variant. Box ends: the

536 upper and lower quartiles. The *horizontal line* inside the box: median. Whisker ends: the
 537 min. and max. of all data. The titers were compared by the Friedman test and Dunn's
 538 multiple comparisons test; two-tailed p-values were calculated.

539

540 **Fig. 4. Changes in the neutralizing antibody titer after booster vaccination in the**

541 **age groups.** The 72 recipients who received the booster vaccination were divided into
 542 three age groups: 31 participants who were ≤ 38 years, 27 participants who were 39–58
 543 years, and 14 participants who were ≥ 59 years. The neutralizing antibody titers against
 544 D614G (A), Delta (B), and Omicron (C) at 2 and 7 months after two doses of
 545 vaccination and after the booster vaccination were compared in each age group. Box
 546 ends: the upper and lower quartiles. The *horizontal line* inside the box: median. Whisker
 547 ends: the min. and max. of all data. The Friedman test and Dunn's multiple comparisons
 548 test were performed; two-tailed p-values were calculated.

A Positive rate of neutralizing antibody at 2 months after the vaccination

B Neutralizing antibody titer at 2 months after the vaccination

A Positive rate of neutralizing antibody at 2 months after the vaccination

B Neutralizing antibody titer at 2 months after the vaccination among three different age groups

A Changes of the neutralizing antibody positive rates **B Changes of the neutralizing antibody titers**

Changes of the neutralizing antibody titers in three different age groups

A D614G

B Delta

C Omicron

A Neutralizing antibody titer and side effects after the second dose of vaccination

B Age and side effects after the second dose of vaccination

eFigure 1. Comparison of side effects and neutralizing antibody titers or recipient's age.

Eighty-two recipients were divided according to the appearance of fever, fatigue, and the degree of injection site pain after the second dose of vaccination. The neutralizing antibody titers (A) and age of recipients (B) were compared by each group. The ends of the box show the upper and lower quartiles, and the median is marked by the horizontal line inside the box. The ends of the "whiskers" represent the minimum and maximum of all data. Lines in eFigure 1B indicate the mean age of recipients in each group. Mann-Whitney U test was performed for the comparison by the presence or absence of fever and fatigue, and Kruskal-Wallis test was performed for the comparison by the degree of injection site pain. Two-tailed p-values were calculated.